Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John P Moore

Showing results (21-30 of 319) with videos related to

Pageof 32
Sort By:
Current Opinion in HIV and AIDS|April 3, 2009
A pièce de resistance: how HIV-1 escapes small molecule CCR5 inhibitorsJohn P Moore, Daniel R Kuritzkes
Retrovirology|October 3, 2012
Good CoP, bad CoP? Interrogating the immune responses to primate lentiviral vaccinesPer Johan Klasse, John P Moore
Science (New York, N.Y.)|May 16, 2024
Progress on priming HIV-1 immunityRogier W Sanders, John P Moore
Cell Host & Microbe|March 11, 2021
Virus vaccines: proteins prefer prolinesRogier W Sanders, John P Moore
Virology|May 29, 2004
Is there enough gp120 in the body fluids of HIV-1-infected individuals to have biologically significant effects?P J Klasse, John P Moore
Nature Medicine|March 5, 2002
AIDS vaccine models: challenging challenge virusesMark B Feinberg, John P Moore
Frontiers in Plant Science|October 21, 2015
Editorial: Current advances and challenges in understanding plant desiccation toleranceJohn P Moore, Jill M Farrant
JAMA|January 28, 2021
SARS-CoV-2 Vaccines and the Growing Threat of Viral VariantsJohn P Moore, Paul A Offit
Journal of Virology|June 28, 2020
COVID-19 Vaccines: "Warp Speed" Needs Mind Melds, Not Warped MindsJohn P Moore, P J Klasse
Nature Immunology|September 17, 2021
Beta testing the monkey modelJohn P Moore, Celine R Gounder
Pageof 32

Showing results (21-30 of 319) with videos related to

Sort By:
Pageof 32
Current Opinion in HIV and AIDS|April 3, 2009
A pièce de resistance: how HIV-1 escapes small molecule CCR5 inhibitorsJohn P Moore, Daniel R Kuritzkes
Retrovirology|October 3, 2012
Good CoP, bad CoP? Interrogating the immune responses to primate lentiviral vaccinesPer Johan Klasse, John P Moore
Science (New York, N.Y.)|May 16, 2024
Progress on priming HIV-1 immunityRogier W Sanders, John P Moore
Cell Host & Microbe|March 11, 2021
Virus vaccines: proteins prefer prolinesRogier W Sanders, John P Moore
Virology|May 29, 2004
Is there enough gp120 in the body fluids of HIV-1-infected individuals to have biologically significant effects?P J Klasse, John P Moore
Nature Medicine|March 5, 2002
AIDS vaccine models: challenging challenge virusesMark B Feinberg, John P Moore
Frontiers in Plant Science|October 21, 2015
Editorial: Current advances and challenges in understanding plant desiccation toleranceJohn P Moore, Jill M Farrant
JAMA|January 28, 2021
SARS-CoV-2 Vaccines and the Growing Threat of Viral VariantsJohn P Moore, Paul A Offit
Journal of Virology|June 28, 2020
COVID-19 Vaccines: "Warp Speed" Needs Mind Melds, Not Warped MindsJohn P Moore, P J Klasse
Nature Immunology|September 17, 2021
Beta testing the monkey modelJohn P Moore, Celine R Gounder
Pageof 32